Synergistic activities of the histone deacetylase inhibitors with conventional cytotoxic chemotherapies in angiosarcomas
Sign Up to like & getrecommendations! Published in 2022 at "Investigational New Drugs"
DOI: 10.1007/s10637-022-01239-1
Abstract: Angiosarcoma is an aggressive type of soft tissue sarcomas with poor prognosis. This calls for investigating and establishing new therapeutic possibilities. Synergistic activities of chemotherapy with newly developed drugs have been tried in other cancer… read more here.
Keywords: cell line; combination; plus doxorubicin; synergistic activities ... See more keywords
The use of cisplatin plus doxorubicin or paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) for stage IIIC or IV epithelial ovarian cancer: a comparative study
Sign Up to like & getrecommendations! Published in 2019 at "Clinical and Translational Oncology"
DOI: 10.1007/s12094-019-02065-3
Abstract: PurposeOur main aim is to analyze the survival results in women operated on for advanced ovarian cancer with two different HIPEC regimens (cisplatin plus doxorubicin versus paclitaxel).Patients and methodsA prospective cohort of patients with stage… read more here.
Keywords: group; ovarian cancer; plus doxorubicin; cancer ... See more keywords
Efficacy and safety of sintilimab plus doxorubicin in advanced soft tissue sarcoma: A single-arm, phase II trial
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.987569
Abstract: Background: Chemoimmunotherapy is safe and efficacious in treating many types of malignant tumors. However, clinical data demonstrating the effect of this combination treatment in patients with metastatic soft tissue sarcoma (STS) are currently limited. This… read more here.
Keywords: safety; sarcoma; sintilimab; trial ... See more keywords